medigraphic.com
Colegio de Medicina Interna de México.

2015, Número 5

<< Anterior Siguiente >>

Med Int Mex 2015; 31 (5)


Consenso de diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana

Peña-Ríos DH, Cisneros-Dreinhofer FA, De la Peña-Rodríguez MP, García-Hernández PA, Hernández-Bueno JA, Jasqui-Romano S, Mercado-Cárdenas VM, Mirassou-Ortega M, Morales-Torres J, Vallejo-Almada J, Vázquez-Alanis A

Idioma: Español
Referencias bibliográficas: 48
Paginas: 596-610
Archivo PDF: 519.49 Kb.


RESUMEN

Antecedentes: la osteoporosis es un problema de salud pública, se asocia con elevada frecuencia de fracturas y es causa importante de morbilidad y mortalidad.
Objetivo: formular una guía de práctica clínica basada en evidencias para el diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica mexicana.
Método: participaron en la elaboración de la guía once médicos de seis especialidades, con experiencia y juicio clínico en el estudio y tratamiento de la osteoporosis. Las recomendaciones se basaron en los criterios diagnósticos y niveles de evidencia de las guías de tratamiento previamente establecidas, ensayos clínicos controlados y guías estandarizadas para las pacientes con osteoporosis.
Resultados: cada especialista actualizó un tema en específico y estableció la evidencia de los diferentes rubros a tratar, según su campo de experiencia clínica, enriquecida por la opinión de los demás expertos. Toda la evidencia y decisiones se unificaron en el documento aquí expuesto.
Conclusiones: se presentan las recomendaciones establecidas por el grupo de expertos y el nivel de evidencia correspondiente para el diagnóstico y tratamiento de la osteoporosis en pacientes posmenopáusicas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Farahmand BY, Michaëlsson K, Ahlbom A, Ljunghall SI, et al. Survival after hip fracture. Osteoporos Int 2005;16:1583-1590.

  2. Johansson H, Clark P, Carlos F, Oden A, et al. Increasing age and sex-specific rates of hip fracture in México: a survey of the Mexican Institute of Social Security. Osteoporos Int 2011;22:2359-2364.

  3. Clark P, Cons-Molina F, Deleze M, Ragi S, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009;20:275-282.

  4. Clark P, Carlos F, Vázquez Martínez JL. Epidemiología, costos y carga de la osteoporosis en México. Rev Metab Oseo y Min 2010;8:152-161.

  5. Kanis JA, McCloskey EV, Johansson H, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.

  6. Murillo-Uribe A, Delezé-Hinojosa M, Aguirre E, Villa A, y col. Osteoporosis en mujeres posmenopáusicas mexicanas. Magnitud del problema. Estudio multicéntrico. Ginecol Obstet Mex 1999;67:227-233.

  7. Clark P, Lavielle P, Franco-Marina F, Ramírez E, et al. Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. Osteoporos Int 2005;16:2025-2030.

  8. Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK, 2008. Disponible en: http://www.shef.ac.uk/FRAX

  9. Babor TF, Higgins-Biddle JC. Brief intervention for hazardous and harmful drinking. A manual for use in primary care, Ginebra: Organización Mundial de la Salud;2001.

  10. Delezé M, Cons-Molina F, Villa AR, Morales-Torres J, et al. Geographic differences in bone mineral density of Mexican women. Osteoporos Int 2000;11:562-569.

  11. Looker AC, Wahner HW, Dunn WL, Calvo MS, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998:8:468-489.

  12. Valoración de riesgo de fractura y su aplicación en el tamizaje de osteoporosis durante la posmenopausia. Reporte del grupo de estudio de la OMS. Ginebra: Organización Mundial de la Salud 2011;serie 843.

  13. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.

  14. Papaioannou A, Morin S, Cheung AM, Atkinson S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-1873.

  15. Cummings SR, Nevitt MC, Browner WS, Stone Ket al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-773.

  16. Lindsay R, Silverman SL, Cooper C, Hanley DA, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.

  17. Nuti R, Brandi ML, Isaia G, Tarantino U, Silvestri S, Adami S. New perspectives on the definition and the management of severe osteoporosis: The patient with two or more fragility fractures. J Endocrinol Invest 2009;32:783-788.

  18. Vasikaran S, Cooper C, Eastell R, Griesmacher A, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011;49:1271-1274.

  19. Osteoporosis. Clinical guideline for prevention and treatment. Executive Summary. National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Orthopaedic Association, British Orthopaedics Research Society, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, Royal College of Physicians and Society for Endocrinology. [en línea]. Dirección URL: .

  20. Moylan KC, Binder EF. Falls in older adults: risk assessment, management and prevention. Am J Med 2007;120:493-497.

  21. Myers AH, Young Y, Langlois JA. Prevention of falls in the elderly. Bone 1996;18:87-101.

  22. Rizzoli R. Nutrition: its role in bone health. Best Pract Res Clin Endocrinol Metab 2008;22:813-829.

  23. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-666.

  24. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

  25. Cauley JA, Robbins J, Chen Z, Cummings SR, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003;290:1729-1738.

  26. Women’s Health Initiative Steering Committee, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.

  27. Gass ML, Heights M, Manson JE, Cosman F, Hayes H, Grodstein F, et al. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.

  28. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.

  29. Gallagher JC, Sai AJ. Biología molecular de la remodelación ósea: implicaciones para los nuevos blancos terapéuticos de la osteoporosis. Rev Metab Oseo y Min 2010;8:60-71.

  30. Black DM, Cummings SR, Karpf DB, Cauley JA, et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.

  31. Black DM, Thompson DE, Bauer DC, Ensrud K, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrin Metab 2000;85:4118-4124.

  32. Harris ST, Watts NB, Genant HK, McKeever CD, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282;1344-1352.

  33. Reginster J, Minne HW, Sorensen OH, Hooper M, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.

  34. Chesnut CH, Skag A, Christiansen C, Recker R, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.

  35. Black DM, Delmas PD, Eastell R, Reid IR, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822.

  36. McClung MR, Geusens P, Miller PD, Zippel H, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.

  37. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-245.

  38. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: a metaanalysis. Osteoporos Int 2006;17:313-316.

  39. Palacios S. Bazedoxifene acetate for the management of postmenopausal osteoporosis. Drugs Today 2011;47:187-195.

  40. Silverman SL, Chines AA, Kendler DL, Kung AW, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351-363.

  41. Lindsay R. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). Osteoporos Int 2011;22:447-451.

  42. Cummings SR, San Martin J, McClung MR, Siris ES, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.

  43. Mendoza N, Sánchez-Borrego R, Villero J, Baró F, et al. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas 2013;76:99-107.

  44. Chesnut CH, Silverman S, Andriano K, Genant H, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-276.

  45. Black DM, Greenspan SL, Ensrud KE, Palermo L, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;249:1207-1215.

  46. Meunier PJ, Roux C, Seeman E, Ortolani S, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468.

  47. Reginster JY, Seeman E, De Vernejoul MC, Adami S, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.

  48. Florence R, Allen S, Benedict L, Compo R, et al. Diagnosis and Treatment of Osteoporosis. Institute for Clinical Systems Improvement2013.




2020     |     www.medigraphic.com